Cancer BiologyBlood NeoplasiaPeer-reviewed
Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphoma
Calixte Calaud, Emilio M. Serrano-López, Leonie A. Cluse…·Pilar M. Domínguez
This study shows that combining a HDAC3 inhibitor with 5-Azacitidine enhances anti-tumor effects against DLBCL in vitro and in vivo, with reduced toxicity compared to single agents.
DOI 10.1016/j.bneo.2026.100214